207 related articles for article (PubMed ID: 12148596)
1. Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases.
Christensson M; Pettersson E; Eneslätt K; Christensson B; Bratt J; Rantapää-Dahlqvist S; Sundqvist KG
J Clin Immunol; 2002 Jul; 22(4):220-7. PubMed ID: 12148596
[TBL] [Abstract][Full Text] [Related]
2. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.
Nozawa K; Kayagaki N; Tokano Y; Yagita H; Okumura K; Hasimoto H
Arthritis Rheum; 1997 Jun; 40(6):1126-9. PubMed ID: 9182923
[TBL] [Abstract][Full Text] [Related]
3. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.
Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Harris J; Hoi AY; Mackay F; Morand EF
Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32546562
[TBL] [Abstract][Full Text] [Related]
4. Serum soluble Fas levels in patients with autoimmune rheumatic diseases.
Sahin M; Aydintug O; Tunc SE; Tutkak H; Naziroğlu M
Clin Biochem; 2007 Jan; 40(1-2):6-10. PubMed ID: 17056024
[TBL] [Abstract][Full Text] [Related]
5. Fas-Fas ligand system in the peripheral blood of patients with renal diseases.
Sato M; Konuma T; Yanagisawa N; Haizuka H; Asakura H; Nakashima Y
Nephron; 2000 Jun; 85(2):107-13. PubMed ID: 10867515
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases.
Jodo S; Kobayashi S; Kayagaki N; Ogura N; Feng Y; Amasaki Y; Fujisaku A; Azuma M; Yagita H; Okumura K; Koike T
Clin Exp Immunol; 1997 Jan; 107(1):89-95. PubMed ID: 9010262
[TBL] [Abstract][Full Text] [Related]
7. Increased serum levels of soluble Fas in progressive B-CLL.
Osorio LM; Aguilar-Santelises M; De Santiago A; Hachiya T; Mellstedt H; Jondal M
Eur J Haematol; 2001 May; 66(5):342-6. PubMed ID: 11422415
[TBL] [Abstract][Full Text] [Related]
8. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons.
Hosaka N; Oyaizu N; Kaplan MH; Yagita H; Pahwa S
J Infect Dis; 1998 Oct; 178(4):1030-9. PubMed ID: 9806031
[TBL] [Abstract][Full Text] [Related]
9. Soluble fas levels correlate with multiple organ dysfunction severity, survival and nitrate levels, but not with cellular apoptotic markers in critically ill patients.
Papathanassoglou ED; Moynihan JA; Vermillion DL; McDermott MP; Ackerman MH
Shock; 2000 Aug; 14(2):107-12. PubMed ID: 10947151
[TBL] [Abstract][Full Text] [Related]
10. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
11. Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis.
Sano H; Asano K; Minatoguchi S; Hiraoka J; Fujisawa K; Nishigaki K; Yasuda N; Kumada H; Takemura M; Ohashi H; Seishima M; Fujiwara T; Fujiwara H
Nephron; 1998 Oct; 80(2):153-61. PubMed ID: 9736812
[TBL] [Abstract][Full Text] [Related]
12. Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours.
Tomokuni A; Aikoh T; Matsuki T; Isozaki Y; Otsuki T; Kita S; Ueki H; Kusaka M; Kishimoto T; Ueki A
Clin Exp Immunol; 1997 Nov; 110(2):303-9. PubMed ID: 9367417
[TBL] [Abstract][Full Text] [Related]
13. Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism.
Nabipour I; Kalantarhormozi M; Assadi M; Jafari SM; Gharibi M; Ahmadi E; Sanjdideh Z
Endocrine; 2010 Dec; 38(3):406-11. PubMed ID: 21042884
[TBL] [Abstract][Full Text] [Related]
14. Membranous and soluble forms of Fas antigen in cutaneous lupus erythematosus.
Fushimi M; Furukawa F; Tokura Y; Itoh T; Shirahama S; Wakita H; Takigawa M
J Dermatol; 1998 May; 25(5):302-8. PubMed ID: 9640883
[TBL] [Abstract][Full Text] [Related]
15. Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C.
Toyoda M; Kakizaki S; Horiguchi N; Sato K; Takayama H; Takagi H; Nagamine T; Mori M
Liver; 2000 Jul; 20(4):305-11. PubMed ID: 10959809
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of soluble Fas ligand in patients with silicosis.
Tomokuni A; Otsuki T; Isozaki Y; Kita S; Ueki H; Kusaka M; Kishimoto T; Ueki A
Clin Exp Immunol; 1999 Dec; 118(3):441-4. PubMed ID: 10594565
[TBL] [Abstract][Full Text] [Related]
17. Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus.
Liphaus BL; Kiss MHB; Carrasco S; Palmeira P; Goldenstein-Schainberg C; Carneiro-Sampaio M
Clin Rheumatol; 2017 Dec; 36(12):2847-2852. PubMed ID: 28378099
[TBL] [Abstract][Full Text] [Related]
18. A possible role of Fas-ligand-mediated "reverse signaling" in pathogenesis of rheumatoid arthritis and systemic lupus erythematosus.
Telegina E; Reshetnyak T; Moshnikova A; Proussakova O; Zhukova A; Kuznetsova A; Ivanov A; Paltsev M; Beletsky I
Immunol Lett; 2009 Jan; 122(1):12-7. PubMed ID: 19010354
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system.
Wang XZ; Chen XC; Chen YX; Zhang LJ; Li D; Chen FL; Chen ZX; Chen HY; Tao QM
World J Gastroenterol; 2003 Dec; 9(12):2671-5. PubMed ID: 14669310
[TBL] [Abstract][Full Text] [Related]
20. Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis.
Alcorta DA; Barnes DA; Dooley MA; Sullivan P; Jonas B; Liu Y; Lionaki S; Reddy CB; Chin H; Dempsey AA; Jennette JC; Falk RJ
Kidney Int; 2007 Oct; 72(7):853-64. PubMed ID: 17667990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
